ORIGINAL RESEARCH article
Front. Cardiovasc. Med.
Sec. Pediatric Cardiology
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1611338
This article is part of the Research TopicAdvancements in Congenital Heart Disease: Diagnosis and Management InnovationsView all 3 articles
Clinical efficacy of percutaneous closure of patent foramen ovale in children diagnosed with migraine
Provisionally accepted
- Tianjin Children's Hospital, Tianjin, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: This retrospective analysis aimed to assess the clinical efficacy of patent foramen ovale (PFO) closure for the treatment of migraine in children. Methods: Data from 35 children diagnosed with migraine and PFO (pre-intervention transthoracic echocardiography did not detect PFO in some, but saline contrast echocardiography was positive, indicating hidden PFO), admitted to Tianjin Children's Hospital for PFO closure between March 2020 and February 2024, were retrospectively collected and analysed. The efficacy of post-intervention pain relief was evaluated using an 11-point numerical rating scale (NRS-11), headache impact test-6 (HIT-6), and Paediatric Migraine Disability Assessment Score (PedMIDAS), migraine frequency, and duration of each migraine attack. Results: At the 1-month follow-up after PFO closure, 20 patients (57.1%) achieved complete relief, and 29 (82.9%) had a reduction in migraine attack frequency by >50%. At the 12-month follow-up, 28 patients (80%) achieved complete relief, and 32 (91.4%) had a reduction in migraine attack frequency by >50%. There were no statistically significant differences between the aura and the non-aura groups. All patients exhibited statistically significant improvement (P<0.05) in NRS-11, HIT-6, and PedMIDAS, migraine frequency, and duration of each migraine attack. The children in the aura group had a more significant decrease in NRS-11 than those in the non-aura group at 12-month after the operation (P<0.05). Additionally, there were no statistically significant differences between the two groups in HIT-6, PedMIDAS, and duration of migraine attacks.Percutaneous PFO closure demonstrated significant clinical efficacy and safety in the treatment of migraine in children.
Keywords: Percutaneous PFO closure, hidden PFO, migraine 1, Children, retrospective analysis, complete relief of headache
Received: 14 Apr 2025; Accepted: 19 May 2025.
Copyright: © 2025 Wang, Liu, Cheng and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dong Li, Tianjin Children's Hospital, Tianjin, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.